Biohaven

Clinical trials are designed to push the boundaries of medical #innovation. We're enrolling patients now to advance cutting-edge #research across multiple diseases. For more information on our ongoing #clinicaltrials, visit: https://bit.ly/4bJ7HCP #ClinicalTrialsDay #CTD2024

We asked our team: Who at Biohaven inspires you? On #InternationalWomensDay, we’re celebrating the women at Biohaven who lead, innovate, and inspire. #IWD #IWD2025

Curious to learn how Biohaven’s first-in-class extracellular #degrader could reshape #immunetherapy? Our extracellular degrader has demonstrated up to 84% IgG reduction in a Phase 1 #trial. Read more about our investigational candidate in this Nature Portfolio article by Asher Mullard featuring Biohaven CEO, Vlad Coric, M.D. and Scientific Advisor, David Spiegel, M.D., Ph.D.: https://bit.ly/45yFiO5 #innovation

Our extracellular #degrader technology is leveraging the body’s natural clearance mechanism to precisely target and remove disease-causing antibodies while preserving essential #immune function. In a Phase 1 study, our investigational candidate achieved up to 84% sustained IgG reductions, marking a major step toward tunable, self-administered immune therapy. Learn more about our latest advancements: https://bit.ly/4ihmAQR #innovation

Hear from Vlad Coric, M.D., this #WorldObesityDay about our focus on tackling #obesity and its complications, including stroke, cardiovascular problems, and diabetes. Aiming to increase muscle mass, burn fat, and reduce glucose and insulin resistance could potentially transform the way we approach obesity care. Learn more: https://brnw.ch/21wR6CC #DaysMatter

NEWS UPDATE: Our investigational candidate, BHV-1300 achieved rapid, deep and sustained IgG reductions of up to 84% in a Phase 1 study, highlighting its potential as a first-in-class #degrader for #autoimmunediseases. Designed for self-administration, it is set to advance into Phase 2 for Graves' disease in mid-2025. Learn more about our progress: https://bit.ly/4ihmAQR  

With 7,000 rare diseases affecting 1 in 10 Americans—and 95% lacking an FDA-approved treatment—there is still much work to do. At Biohaven, we’re dedicated to advancing scientific research and developing much-needed therapies for rare disease patients. Read Melissa Wolfe Beiner, our Senior Medical Director’s perspective on why collaboration and innovation are key to making a difference: https://brnw.ch/21wR1nu #RareDiseaseDay #DaysMatter

In recognition of #RareDiseaseDay, we’re proud to share our dedication to advancing research for rare diseases like #spinocerebellarataxia and #spinalmuscularatrophy. #DaysMatter for those living with #SCA and #SMA, and we are committed to improving their lives through advancing research. #ShowYourStripes #SCAawareness #ataxia #SMAawareness

In the first episode of our new video series, our principal investigator Charlotte Bredo Spliid, Ph.D. explains how we’re breaking boundaries in precision #immunology to help transform the treatment of severe diseases. Check out “Insights on Innovation” to learn how we’re working to solve the toughest medical challenges and meet the scientists making it happen. #Sciencein60 #DaysMatter

Our new video series, “Insights on Innovation” explores the cutting-edge scientific approaches we’re pursuing across our diverse portfolio in #neuroscience, #immunology, and #oncology. Told through the voices of our scientists and researchers, the series brings you closer to our efforts to turn breakthrough science into transformative new medicines. #Sciencein60